>INVESTORS >Financial Highlights

Financial Highlights

Revenue

R&D_Expense

Operating Profit

Net Profit

Announced May 10, 2016

Consolidated operating results

(Billions of Yen)

FY13

FY14

FY15

vs. FY14

increase/

decrease

FY16

Forecasts

Revenue

1,691.7 1,777.8 1,807.4 29.6 1.7% 1,720.0

Overseas revenue

957.8 1,065.0 1,119.3 54.3 5.1% 1,100.0

<% of Revenue>

<56.6%> <59.9%> <61.9%> <2.0pt> <64.0%>

Revenue of ethical drugs segment

1,529.1 1,614.5 1,648.7 34.2 2.1% 1,560.0

R&D expenses*1

341.6 352.9 345.9 -7.0 -2.0% 325.0

<% of Revenue>

<20.2%> <19.9%> <19.1%> <-0.7pt> <18.9%>

Operating profit

139.3 -129.3 130.8 260.1 - 135.0

<% of Revenue>

<8.2%> <-7.3%> <7.2%> <14.5pt> <7.8%>

Profit before income taxes

158.9 -145.4 120.5 266.0 - 132.5

<% of Revenue>

<9.4%> <-8.2%> <6.7%> <14.8pt> <7.7%>

Net profit for the year

109.6 -143.0 83.5 226.5 -

<% of Revenue>

<6.5%> <-8.0%> <4.6%> <12.7pt>

Profit attributable to owners of the Company

106.7 -145.8 80.2 225.9 - 88.0

<% of Revenue>

 <6.3%> <-8.2%> <4.4%> <12.6pt> <5.1%>

Core earnings *2

314.2 288.3 292.4 4.1 1.4%

<% of Revenue>

<18.6%> <16.2%> <16.2%> <-0.0pt>
  • *1 Because of starting the new organizational structure and changing managerial accounting method from FY15, allocation accounts for some expenses have changed. For the purpose to compare FY14 expenses with the FY15 expenses under the same basis (underlying), amounts roughly estimated for this change are adjusted in FY14.
  • *2 Profit from regular business calculated by deducting any temporary factors such as impacts from business combination accounting and from amortization/impairment loss of intangible assets etc., from operating profit.

 

Consolidated financial position
(Billions of Yen) 

FY13 End

FY14 End

FY15 End

vs. FY14 End

Total assets 4,569.1 4,296.2 3,824.1 -472.1
Total liabilities 2,028.5 2,090.0 1,812.9 -277.1
Total equity 2,540.6 2,206.2 2,011.2 -195.0
Equity attributable to owners of the Company 2,470.7 2,137.0 1,948.7 -188.4
Ratio of equity attributable to owners of the Company to total assets 54.1% 49.7%  51.0% 1.2pt

 

SharesFY13 EndFY14 EndFY15 End
Numbers of Shares outstanding (1,000) 789,681 789,924 790,284
Treasury stock (1,000) 213 4,032 6,745
Stock price at year-end (Yen) 4,892 5,999 5,136
Total market value (Billions of Yen) 3,863.1 4,738.8 4,058.9
ROE/EPS/Dividend (Yen)

FY13

FY14

FY15

vs. FY14

Return on equity attributable to owners of the Company 4.5% -6.3% 3.9% -
Basic earnings per share 135.10 -185.37 102.26 -
Annual dividends per share 180.00 180.00 180.00 -
Dividend pay-out ratio 133.2% 176.0% -

 

Exchange rate (Yen)

FY13

FY14

FY15

FY16
Assumptions

US$ Average (Apr.-Mar.) 100 109 121 110
Euro Average (Apr.-Mar.) 133 139 132 125
 FY13 EndFY14 EndFY15 End
Number of employees (Consolidated) 31,225 31,328  31,168